PTO/SB/08a (03-08)
Approved for use through 06/30/2008 OMB 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLO	OSURE
STATEMENT BY APPL	ICANT
(Not for submission under 37 (CFR 1.99)

	Filing Date First Named Inventor Comel Art Unit		10632340			
			2003-08-01			
			elia J. Forster			
			1624			
			ataraman Balasubramanian			
	Attorney Docket Number		VPI/02-119 LIS			

					U.S.I	PATENTS			Remove]	
Examiner Cite Initial* Patent Number Kind Code* Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1										
If you wish	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where, ges or Relev	
	1										
If you wish	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document		vhere Re	or Relevant	т.			
	1										
If you wish	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc), o					Τs

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10632340
Filing Date		2003-08-01
First Named Inventor Come		lia J. Forster
Art Unit		1624
Examiner Name V		ataraman Balasubramanian
Attorney Docket Number		VPI/02-119 US

1	riad, S. et all., Grycogen Symmase Amase-Sp is a regainer Regulator of Cardiomyocyte hypertrophy , J. Cell Biol., 151(1), 117-129 (2000).	
2	Fischer, P. M. et al., "Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutos", Current Med. Chem., 7, 1213-1245 (2000).	
3	Mani, S. et al., "Cyclin-dependent kinase: novel anticancer agents", Exp. Opin. Invest. Drugs., 8, 1849-1870 (2000).	
4	Fry, D.W. et al., "inhibitors of cyclin-dependent kinases as therapsculic agents for the treatment of cancer", Current Opin. Oncol. Endoc. & Metab. Investig., 2-40-59 (2000).	
5	Bokemeyer, D. et al., "Multiple intracellular MAP kinase signaling cascades", Kidney Int., 49, 1187-1198 (1996).	
6	Anderson, N.G. et al., "Multiple intracellular MAP kinase signaling cascades", Nature, 343, 651-653 (1990).	
7	Crevs, C.M. et al., "The Primary Structure of MEK, a Protein Klinase That Phosphorylates the ERK Gene Product", Science, 258, 478-480 (1992).	
8	Bjorbaek, C. et al, "Divergent Functional Roles for p90rsk Kinase Domains", J. Biol. Chem., 270(32), 18848-18552 (1995).	
9	Rouse, J. et al., A Novel Kinase Cascade Tinggered by Stress and Heat Shock That Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins*, Cell, 78, 1027-1037 (1994).	
10	Raingeaud, J et al., MMK3- and MMK6-Regulated Gene Expression is Mediated by p38 Mitogen-Activated Protein Knase Signal Transduction Pathway*, Mol. Cell. Bol., 16, 1247-1255 (1996).	
11	Chen, R.H. et al., "Phosphonylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-klba ribosomal S6 kinase", Proc. Natl. Acad. Sci. USA, 90, 10952-10956 (1953).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10632340		
Filing Date		2003-08-01		
First Named Inventor	Come	lia J. Forster		
Art Unit		1624		
Examiner Name	Venka	Venkataraman Balasubramanian		
Attorney Docket Number		VPI/02-119 US		

Date Considered

	12	Moodie, S.A. et al., "Complexes of Ras-GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase", Science, 260 (5114), 1638-1661 (1993).				
	13	Frey, R.S. et al., "Involvement of Extraositilian Signal-regulated Kinase 2 and Stress-activated Protein Kinase (Jun N- Terminal Kinase Activation by Transforming Growth Factor β in the Negative Growth Control of Breast Cancer Celis", Cancer Res., 57, 628-833 (1997).				
	14	Sivaraman, V.S., et al., "Hyperexpression of Mitogen-activated Protein Kinese in Human Breast Cancer", J. Clin. Invest., 99(7), 1478-1483 (1997).				
	15	Whelchel, A. et al., "Inhibition of ERIX Activation Attenuates Endothelin-stimulated Airway Smooth Muscle Cell Proliferation", Am. J. Respir. Cell Mol. 801, 16, 589-596 (1997).				
	16	Yuan, Z.Q. et al., "Frequent activation of AKT2 and induction of apoplosis by inhibition of phosphonositids-3-OH kinase/Akt pathway in human overian cancer", Oncogene, 19, 2324-2330 (2000).				
	17	Kazuhiko, N. et al., "AstiProtein Kinase B Prevents Injury-Induced Motonsuron Death and Accelerates Axonal Regeneration", J. of Neurosciennoe, 20(8), 2875-2886 (2000).				
	18	Moline, T.J. et al., "Profound block in thymocyte development in mice tecking p56ick", Nature, 357, 161-164 (1992).				
	19	Kimura, M. et al., "Cell Cycle-dependent Expression and Centrosome Localization of a Third Human Auroralipi1- related Protein Kinase, AlkS", J. Biol. Chem., 274(11), 13766-13771 (1997).				
	20	Namikawa, Kazuhiko et al., "AktiProtern Kinsse B Prevents Injury-Induced Motoneuron Death and Accelerates Axonal Regeneration." The Journal of Neuroscience, 20(8), 2875-2896 (2000)				
If you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EFS Web 2.1.2

Examiner Signature